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Abstract 
The original CHOICE measure was designed in collaboration with experts by experience as a 
patient reported ‘Psychological Recovery’ outcome measure for Cognitive Behavioural Therapy 
for Psychosis (CBTp). A short version (CHOICE-SF) was developed to use as a brief outcome 
measure, with a focus on sensitivity to change, for use in future research and practice. CHOICE-
SF was developed and validated using three separate samples, comprising 640 service users 
attending one of two transdiagnostic clinics for (i) CBT for psychosis or (ii) therapies for voice 
hearing or (iii) who took part in the treatment as usual arm of a trial. In the initial sub-sample of 
69 participants, items from the original CHOICE measure with medium to large effect sizes for 
change pre to post CBTp were retained to form the CHOICE-SF. Internal consistency, construct 
validity and sensitivity to change were confirmed, and the factor structure was examined in 242 
participants. Specificity was confirmed by comparison with 44 participants who completed 
CHOICE at two time points but did not receive therapy. Validation of CHOICE-SF was carried 
out by confirming factor structure and sensitivity to change in a new sample of 354, and a sub-
sample of 51 participants, respectively. The CHOICE-SF comprised 11 items and 1 additional 
personal goal item. A single factor structure was confirmed, with high internal consistency, 
construct validity and sensitivity to change. The CHOICE-SF is a brief, psychometrically robust 
measure to assess change following psychological therapies in research and clinical practice for 
people with psychosis and severe mental illness.   
Keywords:  Psychosis, Patient Reported Outcome Measurement, Psychological therapy, 
Cognitive therapy.  
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Introduction 
One of the key interventions for psychosis is Cognitive Behavioural Therapy1. Previous research 
examining the effectiveness of cognitive behavioural therapy for psychosis (CBTp) has mainly 
focused on the reduction of psychosis symptoms, using clinician-rated scales2. However, it has 
been argued that CBTp focuses on alternative outcomes that are not well captured by current 
measures3-4. Specifically, CBTp targets symptom related distress and the impact on functioning, 
associated unhelpful thinking biases, and psychological and emotional recovery, as opposed to 
symptom reduction5-6.  
 
Furthermore, the goals of CBTp are agreed in collaboration with service users, who have 
reported that other issues, such as empowerment, choice, control, and personal fulfilment are of 
central concern7. CBTp, therefore, may address a variety of issues such as negative beliefs about 
psychosis, self-esteem, self-stigma, self-confidence and empowerment8-11.  
 
As a result of this mismatch between CBTp aims and available measures, a new outcome 
measure of CBTp was developed and was designed to reflect both the priorities of CBTp and 
those of the service user (CHoice of Outcome In Cbt for psychoses (CHOICE)12. The initial 
measure was developed in collaboration with service user experts by experience, through 
qualitative analysis and Delphi consultation to reach consensus on the questionnaire items. The 
final measure was found to have one single factor, with good test-retest reliability, face and 
construct validity, and sensitivity to change12. Whilst constituting a single factor, the measure 
included both generic recovery related items, such as ‘feeling happy’ and ‘a sense of being in 
control of my life’, and CBT specific cognitive and coping items such as ‘positive thinking’, 
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‘ways of dealing with unpleasant feelings and emotions’ and ‘ways of dealing with distressing 
experiences’. Since publication, the original CHOICE measure has been used in at least four 
randomised trials and three observational studies to assess the effectiveness of various 
psychological interventions including mindfulness, structured communication, relating therapy 
as well as group-based, self-help and one-to-one CBT in individuals with psychosis 
experiences13-19. It has been referenced in recent policy documents20 and has been adopted by 
routine clinical services in at least 10 NHS trusts around the UK, as well as by UK clinical 
psychology training departments, and international services in Asia, America and Europe, where 
it has been translated into other languages21. It has been described as an important measure of 
‘self- defined recovery that may be valued more highly than symptom reduction alone by many 
service users’4. 
 
The original CHOICE questionnaire comprised 24 items, covering a range of issues, each rated 
on two separate sub-scales of severity and satisfaction. Participants first rated the severity of 
each item on a Likert scale from 0 (worst) to 10 (best), and then rated their level of satisfaction in 
relation to each item on a separate Likert scale from 0 (not at all satisfied) to 10 (very satisfied). 
However, the length of the original CHOICE measure was a potential drawback, as participants 
were required to make 48 individual ratings which may be a challenge for some people with 
psychosis where characteristic difficulties with concentration, motivation and cognition may 
hamper completion22-23. Furthermore, there was a specific need for a measure that could be used 
to measure change over short time frames, including on a session-by-session basis, as part of the 
Improving Access to Psychological Therapies in Severe Mental Illness (IAPT-SMI) programme. 
This study therefore aimed to develop a brief, psychometrically robust and clinically valuable 
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version of CHOICE that would also be highly sensitive to change over a short (one week) time 
frame. Initial development commenced, at the start of the IAPT-SMI programme in 2013, and 
validation has subsequently been conducted across several distinct phases in a large sample of 
participants receiving psychological therapies.    
 
Methods 
A total of 640 patients with psychosis experiences and Severe Mental Illness (in receipt of 
secondary care services) contributed data in one of two phases: (i) the initial development; or the 
(ii) the secondary validation of the CHOICE short form (CHOICE-SF). 
  
Development phase  
Participants. 
The initial participants were 69 psychosis service users from the Psychological Interventions 
Clinic for outpatients with Psychosis (PICuP) run by the South London and Maudsley NHS 
Foundation Trust. They received CBTp according to NICE guidelines and provided full choice 
data at two time points: 1) an initial screening assessment (either prior to joining the waiting list 
(n=45) or immediately pre-therapy (n=24)); and 2) post CBTp. See Peters et al. for further details 
about assessment procedures and therapy in PICuP24. A larger sample of 242 individuals with 
psychosis from PICuP, which included these 69 participants, completed the original full 
CHOICE measure on at least one of 5 time points (initial screening, immediately pre-therapy, 
mid-therapy, post-therapy or follow up) and provided data for the initial factor analysis. 
Measures 
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Service users were asked to complete 5 measures as part of routine data collection by the clinic. 
All measures have good reliability and validity in a psychosis sample.  
(i) The original CHOICE measure12 - a 24-item self-report questionnaire, which provides 
mean scores for severity and satisfaction with a range of aspects of psychological 
wellbeing, as well as additional self-reported items or therapy goals that are unique to 
the individual. Each item is reported on an 11 point scale from 0 (worst) to 10 (best). 
The mean score is used. 
(ii) The Beck Depression Inventory (BDI)25 - a 21-item measure of depressive symptoms and 
cognitions, on which each item is rated on a 4-point scale from 0-3 to produce a total 
score, from 0-63, where higher scores reflect more severe symptoms. 
(iii) The Beck Anxiety Inventory (BAI)26 - a 21-item measure of physiological anxiety 
symptoms, on which each item is rated on a 4-point scale from 0 (not at all) to 3 
(severely) to produce a total score, from 0-63, where again high scores reflect more 
severe symptoms. 
(iv) The Manchester Assessment of Quality of Life (MANSA)27 - a 16-item measure that 
assesses satisfaction with life across 12 subjective measures and 4 objective measures 
including areas such as employment, finances, leisure, friendships, relationships, 
personal safety, accommodation, and physical and mental health. Each item is rated 
on a 7-point scale from 1 (couldn’t be worse) to 7 (couldn’t be better). The total score 
was used. 
(v) The Psychotic Symptoms Rating Scale (PSYRATS)28 – which comprises a 17 item, five 
point (0-4) scale, multidimensional measure. The delusion scale comprises 6 items 
that capture distress, disruption, preoccupation and conviction (scores range from 0-
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24). The Hallucinations Scale has 11 items that include frequency, duration, loudness, 
location, intensity, distress, disruption, negative content and beliefs about origin 
(scores range from 0-44).  
 
A comparison group of 44 participants with a diagnosis of schizophrenia, completed the full 
CHOICE at two time points 16 weeks apart, as part of the Treatment As Usual control arm of a 
randomized trial conducted separately by our group16. 
 
Statistical Analysis 
The severity and satisfaction scales of the original CHOICE measure are highly correlated. In the 
interests of developing a much briefer scale, only the CHOICE severity scale was selected, as it 
is a simpler construct than satisfaction which is impacted conceptually by knowledge of 
opportunities and expectancies, and methodologically by overlaps with health outcomes29-30. 
Cohen’s d effect sizes were calculated to reflect the change on each of the individual items of the 
CHOICE measure, using the pre-CBTp standard deviation and mean difference pre-post therapy 
for the 69 participants who provided data pre- and post-CBTp. Items where the effect size was 
medium-large (Cohen’s d > 0.55) were retained, whilst those with smaller effect sizes (.28-.54) 
were omitted. Using this same sample of 69 participants, internal consistency (Cronbach’s alpha) 
and sensitivity to change (one-way ANOVA) were also calculated, and specificity was confirmed 
by comparison with the 44 participants who provided full CHOICE data at 2 time points, from 
which the short form was derived, but who did not receive therapy. Construct validity was 
assessed by correlating pre-therapy scores from the CHOICE-SF with the BDI, BAI, MANSA 
and PSYRATS. The reliable change index31-33 and factor structure were also calculated in the 
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whole sample of 242 participants, the latter using principal axis factoring. The Kaiser-Meyer-
Olkin (KMO) value was 0.91, and the Bartlett’s Test of Sphericity reached significance, thus 
supporting the suitability of the data for factor analysis. Sample sizes were large, and greater than 
those reported for reliability and factor analysis in the original CHOICE paper. The single factor, 
high loading items, communalities in the 0.5 range, with > 20-30 participant per item provide 
sufficient power and a robust factor structure for both EFA and CFA analysis34-36. For the 
sensitivity analysis, a sample size calculation based on a medium pre-post effect size consistent 
with published literature (Cohen's d=0.4) using a 2-sided paired t-test at the 5% alpha level and 
80% power, resulted in a minimum required sample size of N=59. 
 
Secondary Validation Phase.  
Participants 
The factor structure of the CHOICE-SF was further examined using data provided by a further 
354 transdiagnostic voice-hearing participants who attended an initial assessment at the Sussex 
Voices Clinic (a specialist outpatient service offered by Sussex Partnership NHS Foundation 
Trust) between May 2014 and June 2018, and completed the CHOICE-SF. Sensitivity to change 
of the CHOICE-SF was examined in 51 of these 354 participants who also completed the 
CHOICE-SF following at least 2- 4 sessions of Coping Strategy Enhancement for voices37 
delivered by therapists with a range of expertise, and either: 8-12 sessions of group person based 
cognitive therapy for distressing voices16, 6-16 sessions of individual relating and assertiveness 
therapy for voices18, or 6-8 sessions of individual Guided self-help cognitive behavioural 
Intervention for distressing VoicEs19, delivered by expert therapists.  
Analysis 
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In the second validation phase, an a priori model of the questionnaire data was tested using 
Confirmatory Factor Analysis based on a sample of N=354 participants. The analysis was 
performed in the R software environment38, using the lavaan package 39, and plots were created 
using lavaanPlot40. Full Information Maximum Likelihood estimation was used in order to 
handle missing data points whilst improving bias and efficiency41. In addition to the Chi-Square 
test of exact fit, model fit was assessed using global and local fit indices: CFI (Comparative Fit 
Index)42, TLI (Tucker-Lewis Index)43, GFI (Goodness of Fit Index), as well as RMSEA (root 
mean square error of approximation)44 and SRMR (standardized root mean square residual)45. 
The magnitude and significance of factor loadings of the resulting model was also evaluated. 
 
Two paired t-tests were then conducted to test the measure's sensitivity to change between 
baseline and follow-up: the first using the mean score of the 11 CHOICE-SF items; and the 
second using the personal goal item alone. The personal goal item was analysed separately, as 
this item is personal to the individual and is not necessarily completed by all service users. Bayes 
factors were also calculated where possible, as they enable a distinction between results that 






Characteristics of the participants who took part in the development of the CHOICE-SF can be 
found in Table 1.  
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[Insert Table 1 about here] 
 
Development of the short form  
Item selection 
12 out of 24 items had medium-large effect sizes (Cohen’s d ranging from 0.55-0.77) for change 
with CBTp in the full (n = 69), and even larger effect sizes (Cohen’s d ranging from 0.64-0.98) in 
the smaller sub-sample (n=24/69) with immediate pre-post therapy data. One of these items: 
‘The ability to question the way I look at things’ overlapped conceptually with another ‘The 
ability to see things from another point of view’, and internal consistency was found to be 
marginally greater (Cronbach’s α = 0.93) with the former item. Therefore, only the first was 
included, to provide a final CHOICE short form measure (see Supplementary materials for the 
final CHOICE-SF) comprising 11 items, and 1 blank item for recording a personal goal.  
 
Internal consistency, construct validity and sensitivity to change 
The final CHOICE-SF had high internal consistency [Cronbach’s α = 0.93], and was highly 
sensitive to change with CBTp [ df(68), t= -6.08, p<.001, (CI(95) = -2.19 - -1.10)] with a large 
effect size for change [Cohen’s d =- 0.84;  (CI(95) = -1.15 - -0.54)]. The same sensitivity and 
effect size calculations for the original full CHOICE in the same 69 participants, yielded slightly 
lower effect size, [df(68), t= -5.56, p<.001, (CI(95) = -1.98 - -0.93); Cohen’s d =- 0.73;  (CI(95) = -
1.03 - -0.44)]. In contrast, and in support of the specificity of change to the intervention, the 
comparison group who received no intervention, experienced no significant change on the 
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CHOICE-SF [df(43), t= -1.09, p=0.28, (CI(95) = -1.09 - 0.20); Cohen’s d = -0.15; (CI(95) = -0.57 - 
0.27)] 
 
Construct validity was good with the CHOICE-SF mean score correlating positively with the 
MANSA (r=0.70 p<.001) and negatively with the BDI (r= -0.70 p < .001 n=68) and BAI (r = -
0.52 p<.001 n=68). However, the CHOICE-SF did not correlate with the PSYRATS delusions 
(r= -0.277 p=.069 n=45) or voices scales (r= -0.313 p=.098 n=30). These findings are consistent 
with and stronger than those for the original CHOICE measure where the severity scale 
correlated significantly with the MANSA (r=0.52), BDI (r=-0.70), BAI (r=-0.48), 
distress/disruption items on the PSYRATS (r=-0.26-0.28), but not with traditional PSYRATS 
symptom measures of conviction with delusions ( r=0.11), or frequency, location or beliefs about 
voices (r=0.01 to 0.10)12.   
 
Initial Factor Analysis  
Following item selection, internal consistency, validity and sensitivity analysis, a principal axis 
factoring analysis, was conducted on the larger sample of 242 participants. This revealed a single 
factor with an eigenvalue exceeding 1, which explained 52.3%, of the variance. The factor 
loadings are presented in Table 2.  
[Insert Table 2 about here] 
 
The reliable change index 
The Reliable Change Index (RCI)31-33 for CHOICE-SF was calculated for items 1-11 only (as the 
goal item is not used by all service users), using the standard deviation (SD=1.983) from the full 
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242 participant sample. The RCI was found to be 1.45, indicating that a change in mean score of 
1.45 points or more is considered a statistically reliable change. This compares to the RCI 
derived from the standard deviation (1.93) and reliability (0.83) of the original CHOICE 
questionnaire12 of 2.2 points.  With regards to the initial development sample (n=69), 82% of this 
sample demonstrated some improvement, i.e. an increase in total score, on the CHOICE-SF 
following CBTp and over half of participants (53%) showed a statistically reliable improvement, 
of at least 1.45 points on the CHOICE-SF. 
 
Secondary validation of the short form. 
Participants 
Characteristics of participants who took part in the secondary validation can be found in Table 3.  
[Insert Table 3 about here] 
 
Secondary factor analyses 
For the CFA model of a single ‘Psychological Recovery’ factor with 11 indicators, the Chi-
Square test was significant, χ²=175.408, df=44, p<.001, as can occur in smaller datasets. Other fit 
indices suggested a good or acceptable level of approximate fit: CFI=0.942, TLI=0.942, 
GFI=0.953, RMSEA=0.092, CI(90) [0.076; 0.106] and SRMR=0.042. In order to evaluate 
potential errors of model specification, the standardised residuals matrix was evaluated as 
suggested by Kline48. Two adjacent items (Q9: Understanding myself and my past and Q10: 
Understanding my experiences) were found to have a high (>|.10|) residual. 
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The CFA model allowing for correlated errors between Q9 and Q10 improved model fit resulting 
in a lower but significant Chi Square value, χ²=92.124, df=43, p<.001. Other indices also 
suggested an improved fit compared to the previous model, CFI=0.978, TLI=0.972, GFI=0.975. 
The root mean square error of approximation estimate was RMSEA=0.057, CI(90)  [0.041; 0.073] 
allowing the rejection of the poor-fit hypothesis (<.10). The SRMR also decreased and was 
below the value of 0.08, SRMR = 0.029. All factor loading (ranging from 0.667 and 0.815) were 
significant indicators of Psychological Recovery, as displayed below in Table 4. 
 
Secondary sensitivity to change 
The t-tests assessing sensitivity to change again revealed a significant difference between 
baseline and post-therapy mean score for the CHOICE-SF (11 items) [df(50), t = 5.34, p<0.001, 
(CI(95) = 2.04 - .92), Bayes factor = 38614). A larger significant difference was found for the 
personal goal item [df(53), t = 7.93, p < 0.0001, (CI(95) = 2.19 - 3.67),  Bayes factor = 846). 
Bayes factors were greater than 100, which demonstrates that these effects are strong evidence of 
change over time with CBTp47. 
 
Discussion 
We aimed to develop and validate a short version of the CHOICE measure for use in research 
and clinical practice, with a specific view to it being sensitive and suitable for use over short-
time scales and on a sessional basis. A one-page version (CHOICE-SF) was developed from the 
original severity scale, containing 11 items + 1 personal goal, which retained a clear single factor 
structure, was highly sensitive to change and showed high internal consistency, validity and 
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utility for research and clinical practice, as evidenced by its already rapid adoption in a broad 
range of contexts 11, 49-64 .  
 
The CHOICE-SF continues to incorporate both cognitive and coping outcomes that are amenable 
to change with CBTp, as well as well-being outcomes such as peace of mind. The single factor 
structure was stable across 2 datasets from different clinics in different mental health services. It 
correlated closely with affect and quality of life, but not delusions and voices measures, and as 
such supports its discriminant validity from positive symptom measures.    
 
Since the development of the CHOICE-SF it has already been used in six recent or on-going 
trials11, 49-53 , three pilot-feasibility studies54-56, two case studies57-58, one case series59 and five 
observational studies60-64. However, as noted by Stevens and colleagues64, no psychometric 
properties have been available for this short form. Fornells-Ambroio et al. 61, used the CHOICE-
SF at every session in an IAPT-SMI demonstration site for people with psychosis. The authors 
found that the CHOICE-SF was well received, with 71% (n = 64) of clients surveyed at the end 
of therapy reporting it to be actively helpful. Qualitative analysis found that using the CHOICE-
SF was helpful for monitoring improvements although it could be less helpful when progress was 
not being made. Furthermore, the goal-setting item in the CHOICE-SF was particularly valued 
by service users61. In a further paper from the same IAPT-SMI site, the authors reported that 
paired completion rates i.e., a minimum of two CHOICE-SF being completed over the course of 
therapy, were high at 97%60. Interestingly this paper also showed that 77% of patients showed 
some improvement in CHOICE score following CBTp and 55% showed significant reliable 
change. These figures are highly consistent with those reported in the current paper where 82% 
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of participants showed some improvement and 53% showed reliable change. These studies show 
that the CHOICE-SF can be implemented and is acceptable and successful in demonstrating 
reliable change as a routine outcome measure. It can be used within clinical services, including 
in an IAPT-SMI demonstration site, and in research trials that evaluate psychological therapies 
for a range of issues including paranoia, sleep, worry and self-confidence.  
 
The study has several strengths. We have validated the psychometric properties in two 
transdiagnostic participant populations, one incorporating psychosis symptoms and the second 
being voice hearers specifically, with different gender distribution. This demonstrates that the 
measure is valid and sensitive to change in a mixed sample of people severe mental illness, 
including borderline and emotional unstable personality disorders, complex trauma and 
depression as well as psychosis. Furthermore, people from black Caribbean or African 
populations are 2.4 to 14.4 times more likely to develop psychosis compared to other ethnic 
groups65-66. This ethnic variation is captured in the initial sample where 26% of service users 
were black Caribbean or African, this suggesting that the CHOICE-SF can be used across a 
mixed, heterogeneous population. It has similar internal consistency and validity, but enhanced 
sensitivity to change compared to the original measure, and facilitates a focus on other aspects of 
change besides positive symptom. It retains a personal goal item which is liked by service users, 
valuable in shaping therapy focus, and particularly sensitive to change. Although we have not 
directly compared acceptability and ease of use between CHOICE and CHOICE-SF, the latter is 
much shorter, and simpler to complete and score, comprising only one sub-scale, making it 
highly valuable for use in research and routine clinical services.    
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In terms of limitations, the initial item selection, internal consistency and construct validity of the 
CHOICE-SF were calculated in a comparatively small sample. Item selection was informed by 
effect sizes which are not influenced by sample size, and although small samples, can lead to 
biases in sample selection, the current study utilised an unselected heterogenous clinical sample, 
with high ecological validity. The sample size may have contributed to the lack of significant 
correlation with psychosis symptoms, in contrast to quality of life and emotional symptoms. The 
low correlation values with psychosis symptoms, are however, in line with the recovery and 
CBTp literature, and with our previous study, where psychosis symptoms are not necessarily 
related to well-being or to important CBTp outcomes. Black African and Caribbean service users 
were slightly under-represented in the secondary validation sample (2% compared to 3% in the 
general population)67 with some under-representation of Asian populations in both samples, 
(General population = 6.9% vs Initial validation = 2.90% and Baseline secondary validation 
sample = 4%).  
 
Conclusions  
The CHOICE-SF is an 11-item patient reported service-user led psychological recovery outcome 
measure with high validity, internal consistency and sensitivity to change, with an additional 
item for a personal goal, which has been found to be highly regarded by service users61. It is 
applicable to a broad and heterogeneous service user population and can be employed on a 
session-by-session basis to evaluate psychological therapy outcomes for Severe Mental Illness.  
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